Innohep 20,000 IU/ml Injection for VTE: Uses and Safety
Quick summary Innohep 20,000 IU/ml solution for injection contains tinzaparin sodium, a low-molecular-weight heparin used in the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism. It is...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Innohep 20,000 IU/ml solution for injection contains tinzaparin sodium, a low-molecular-weight heparin used in the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism. It is given by subcutaneous injection and dosing is typically based on clinical assessment and body weight.
Medical disclaimer: This article is for general information only. It does not replace the official patient leaflet, prescribing information, or advice from a doctor, nurse, or pharmacist. Do not use this page to self-diagnose or to change any treatment plan.
What is Innohep 20,000 IU/ml solution for injection?
Innohep 20,000 IU/ml solution for injection is a prescription medicine containing tinzaparin sodium. It belongs to the group of medicines known as low-molecular-weight heparins (LMWHs).
It is used in medical practice for the prevention and treatment of blood clots, especially venous thromboembolism (VTE). This includes conditions such as deep vein thrombosis (DVT) and pulmonary embolism.
The medicine is administered by subcutaneous injection. In clinical use, the dose and duration are determined by the healthcare professional based on the patient’s situation.
How does Innohep work in VTE?
Innohep helps reduce clot formation by supporting the action of antithrombin III. This affects key clotting factors involved in the blood coagulation process, including thrombin and factor Xa.
By reducing the blood’s tendency to clot, it helps manage venous thromboembolism and lowers the risk of further clot-related complications.
Because it is an anticoagulant, the main safety concern is bleeding. That is why careful medical supervision is important during treatment.
Common uses of Innohep
- Treatment of venous thromboembolism
- Management of deep vein thrombosis
- Management of pulmonary embolism
- Prevention of clot formation in patients at increased risk, including some post-operative situations
Use depends on the clinical context and the prescribing clinician’s assessment.
How is the dose usually determined?
The original content notes that dosing is generally based on body weight, with a standard regimen of 175 anti-Xa IU/kg given subcutaneously in some treatment settings. It also notes that treatment may continue for at least six days depending on the clinical situation.
In practice, the exact dose, timing, and duration should be confirmed from the prescription and official product information. Some patients may need closer monitoring, especially if there are changes in kidney function or other medical factors.
| Topic | What to verify |
|---|---|
| Dose | The prescribed amount and whether it is weight-based |
| Duration | How long treatment should continue |
| Monitoring | Whether blood tests or anti-Xa monitoring are needed |
| Injection technique | How and where the injection should be given |
Who should not use it without medical review?
The original content highlights several situations where Innohep should be avoided or used with caution. These include:
- Known hypersensitivity to low-molecular-weight heparins
- Active bleeding disorders
- Severe thrombocytopenia
- Situations involving neuraxial anesthesia, such as epidural procedures, because of bleeding risk
Caution is also especially important in older adults and in people with renal impairment. A clinician should review the full medical history before treatment is started.
What side effects should be watched for?
Innohep is generally described as well tolerated, but the main risk to watch for is bleeding. Signs may include unusual bruising, prolonged bleeding from cuts, or blood in urine or stools.
Other effects mentioned in the source content include:
- Injection site pain, redness, or swelling
- Rash or itching
- Thrombocytopenia, meaning a low platelet count
Any concerning symptom should be reported promptly to a healthcare professional.
Important precautions before use
Before Innohep is used, the healthcare team usually checks for factors that may increase bleeding risk or affect treatment safety.
- Review kidney function if relevant
- Check for other medicines that may affect clotting
- Confirm the correct injection technique
- Inspect the solution before use; it should be clear and free from visible particles
Proper training is important if the injection is to be given outside a hospital setting.
Which medicines may interact with Innohep?
The source content notes that Innohep may interact with other medicines that increase bleeding risk or affect anticoagulant action.
- Other anticoagulants, such as warfarin
- NSAIDs, which may increase bleeding tendency
- Certain antibiotics and antifungal medicines
Because interaction risk depends on the full medicine list, patients should tell their clinician or pharmacist about all prescription medicines, over-the-counter products, and supplements they use.
How is Innohep administered?
Innohep is given as a subcutaneous injection, commonly into the thigh or abdomen. If self-injection is required, the person should receive clear instruction on technique and site rotation.
In a clinical setting, administration should follow local protocols and hygiene standards.
Key points to confirm with a doctor or pharmacist
- The exact reason for treatment
- The prescribed dose and schedule
- Whether any blood tests are needed
- How to recognise bleeding or injection-site problems
- What to do if a dose is missed or if a problem occurs
Frequently asked questions
▸ What is Innohep injection used for?
It is used for the prevention and treatment of venous thromboembolism, including DVT and pulmonary embolism.
▸ What is the active ingredient in Innohep?
The active ingredient is tinzaparin sodium, which is a low-molecular-weight heparin.
▸ How is Innohep usually given?
It is given by subcutaneous injection, often into the thigh or abdomen, according to the prescribed instructions.
▸ What are the main safety concerns?
Bleeding is the main concern. Injection-site reactions and low platelet counts are also mentioned in the source content.
▸ Do I need monitoring while using it?
Some patients may need monitoring, especially if kidney function is reduced or if the clinician wants to check anticoagulant effect.
Safety reminder: If you notice signs of bleeding, a severe allergic reaction, or any sudden worsening of symptoms, seek urgent medical advice. Always follow the official leaflet and the instructions given by your healthcare team.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Electronic Medicines Compendium (emc) – Innohep SmPC
- NHS – Anticoagulants
- British Society for Haematology – Venous thromboembolism resources
- MedlinePlus – Heparin injection information
- NICE – Venous thromboembolism guidance
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.